These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 27272086)

  • 1. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
    Lowe E; Lim S
    J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.
    Gold LS; Papp K; Lynde C; Lain E; Gooderham M; Johnson S; Kerrouche N
    J Drugs Dermatol; 2017 Sep; 16(9):909-916. PubMed ID: 28915286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
    Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
    Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
    J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
    Cookson H; McFadden J; White J; White IR
    Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
    [No Abstract]   [Full Text] [Related]  

  • 6. Dermatitis medicamentosa: severe rebound erythema secondary to topical brimonidine in rosacea.
    Werner K; Kobayashi TT
    Dermatol Online J; 2015 Jan; 21(3):. PubMed ID: 25780983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythema in Skin Adjacent to Area of Long-term Brimonidine Treatment for Rosacea: A Novel Adverse Reaction.
    Gillihan R; Nguyen T; Fischer R; Rajpara A; Aires D
    JAMA Dermatol; 2015 Oct; 151(10):1136-7. PubMed ID: 26083825
    [No Abstract]   [Full Text] [Related]  

  • 8. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
    Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
    Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea.
    Johnson AW; Johnson SM
    Dermatol Ther (Heidelb); 2015 Sep; 5(3):171-81. PubMed ID: 26112098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy.
    Gerber PA
    Br J Dermatol; 2016 Jun; 174(6):1422-3. PubMed ID: 26727630
    [No Abstract]   [Full Text] [Related]  

  • 11. Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions.
    Oon HH; Lim ZV
    Australas J Dermatol; 2017 Feb; 58(1):63-64. PubMed ID: 26763464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
    Moore A; Kempers S; Murakawa G; Weiss J; Tauscher A; Swinyer L; Liu H; Leoni M
    J Drugs Dermatol; 2014 Jan; 13(1):56-61. PubMed ID: 24385120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%.
    Routt ET; Levitt JO
    J Am Acad Dermatol; 2014 Feb; 70(2):e37-8. PubMed ID: 24438976
    [No Abstract]   [Full Text] [Related]  

  • 14. A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea.
    Hofmann MA; Kokolakis G
    J Cosmet Laser Ther; 2017 Aug; 19(4):222-224. PubMed ID: 28139145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study.
    El-Domyati M; Rezk AF; Nasif G; Abdelhameed SS; Medhat W
    Int J Dermatol; 2023 Jul; 62(7):888-894. PubMed ID: 37212604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
    Steinhoff M; Schmelz M; Schauber J
    Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea.
    Pakdaman SF; Samadi A; Fattahi M; Naeimifar A; Ardehali FA; Ketabi Y; Nasrollahi SA; Firooz A
    J Cosmet Dermatol; 2024 Sep; 23(9):2973-2981. PubMed ID: 38831548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
    Benkali K; Leoni M; Rony F; Bouer R; Fernando A; Graeber M; Wagner N
    Br J Dermatol; 2014 Jul; 171(1):162-9. PubMed ID: 24506775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component.
    Micali G; Dall'Oglio F; Verzì AE; Luppino I; Bhatt K; Lacarrubba F
    Lasers Med Sci; 2018 Aug; 33(6):1397-1400. PubMed ID: 28889348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.
    Jackson JM; Fowler J; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M;
    J Drugs Dermatol; 2014 Jun; 13(6):699-704. PubMed ID: 24918560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.